Global Theranostics Market Size study & Forecast, by Application (Oncology, Neurology, Cardiology, Infectious Diseases), by Technology (Genomics, Proteomics, Metabolomics, Biomarkers), and Regional Forecasts 2025-2035

Description

The Global Theranostics Market, valued at approximately USD 9.17 billion in 2024, is projected to expand at an impressive CAGR of 11.77% between 2025 and 2035. Theranostics, an innovative field that merges diagnostics with targeted therapy, is transforming the landscape of precision medicine by enabling clinicians to both detect and treat diseases using a single, integrated approach. By leveraging advanced molecular imaging, biomarker profiling, and companion diagnostics, theranostics facilitates personalized treatment strategies that significantly improve patient outcomes while reducing unnecessary therapeutic interventions. The rising prevalence of chronic and life-threatening conditions such as cancer, cardiovascular disorders, and neurological diseases is catalyzing demand for these advanced solutions. Increasing investment in genomic and proteomic research, coupled with advances in molecular imaging modalities, is further propelling market growth as healthcare systems pivot toward outcome-based care models.

The surge in adoption of theranostic approaches stems from their ability to shorten diagnostic timelines, optimize treatment regimens, and minimize adverse effects. In oncology, theranostics is proving to be a game changer by pairing diagnostic imaging agents with targeted radiopharmaceuticals to treat tumors more effectively. According to recent clinical trial data, patient survival rates for certain cancers have improved markedly when theranostic solutions were deployed early in the treatment cycle. Furthermore, the integration of AI-powered analytics with biomarker-based screening is enabling healthcare providers to detect disease progression at a molecular level long before symptoms emerge, opening new avenues for preventive medicine. Despite these advancements, the market faces challenges such as high development costs, stringent regulatory frameworks, and limited access to cutting-edge diagnostic infrastructure in low-resource regions.

Regionally, North America is anticipated to maintain its leadership position in the theranostics market in 2025, supported by robust R&D investment, a well-established biopharmaceutical sector, and rapid adoption of precision medicine frameworks. The region's favorable reimbursement landscape, combined with the presence of leading diagnostic imaging and pharmaceutical companies, further cements its dominance. Europe follows closely, driven by strong government initiatives promoting personalized healthcare, as well as growing academic-industry collaborations in biomarker discovery. The Asia Pacific region is expected to witness the fastest growth over the forecast period, fueled by expanding healthcare infrastructure, surging demand for early disease detection, and an increasing prevalence of lifestyle-related disorders. Nations like China, India, and Japan are investing heavily in advanced molecular diagnostic platforms and clinical research programs to address rising healthcare burdens.

Major market player included in this report are:

Siemens Healthineers AG
GE HealthCare Technologies Inc.
F. Hoffmann-La Roche Ltd.
Thermo Fisher Scientific Inc.
Abbott Laboratories
Philips Healthcare
Agilent Technologies, Inc.
Illumina, Inc.
Danaher Corporation
Qiagen N.V.
Bayer AG
Bracco Imaging S.p.A.
Cardinal Health, Inc.
PerkinElmer, Inc.
Lantheus Holdings, Inc.

Global Theranostics Market Report Scope:

Historical Data - 2023, 2024
Base Year for Estimation - 2024
Forecast period - 2025-2035
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa
Customization Scope - Free report customization (equivalent up to 8 analysts' working hours) with purchase. Addition or alteration to country, regional & segment scope*

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values for the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within the countries involved in the study. The report also provides detailed information about crucial aspects, such as driving factors and challenges, which will define the future growth of the market. Additionally, it incorporates potential opportunities in micro-markets for stakeholders to invest, along with a detailed analysis of the competitive landscape and product offerings of key players. The detailed segments and sub-segments of the market are explained below:

By Application:

Oncology
Neurology
Cardiology
Infectious Diseases

By Technology:

Genomics
Proteomics
Metabolomics
Biomarkers

By End User:

Hospitals
Diagnostic Laboratories
Research Institutes

By Product Type:

Instruments
Reagents
Software

By Region:

North America
U.S.
Canada
Europe
UK
Germany
France
Spain
Italy
ROE
Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC
Latin America
Brazil
Mexico
Middle East & Africa
UAE
Saudi Arabia
South Africa
Rest of Middle East & Africa

Key Takeaways:

Market Estimates & Forecast for 10 years from 2025 to 2035.
Annualized revenues and regional level analysis for each market segment.
Detailed analysis of geographical landscape with Country level analysis of major regions.
Competitive landscape with information on major players in the market.
Analysis of key business strategies and recommendations on future market approach.
Analysis of competitive structure of the market.
Demand side and supply side analysis of the market.

Chapter 1. Global Theranostics Market Report Scope & Methodology

1.1. Research Objective
1.2. Research Methodology
- 1.2.1. Forecast Model
- 1.2.2. Desk Research
- 1.2.3. Top Down and Bottom-Up Approach
1.3. Research Attributes
1.4. Scope of the Study
- 1.4.1. Market Definition
- 1.4.2. Market Segmentation
1.5. Research Assumption
- 1.5.1. Inclusion & Exclusion
- 1.5.2. Limitations
- 1.5.3. Years Considered for the Study (Historical Data - 2023, 2024; Base Year for Estimation - 2024; Forecast period - 2025-2035)

Chapter 2. Executive Summary

2.1. CEO/CXO Standpoint
2.2. Strategic Insights
2.3. ESG Analysis
2.4. Key Findings

Chapter 3. Global Theranostics Market Forces Analysis

3.1. Market Forces Shaping The Global Theranostics Market (2024-2035)
3.2. Drivers
- 3.2.1. Rapid rise in precision medicine adoption and oncology-targeted radiopharmaceutical development
- 3.2.2. Increasing investment in genomics/proteomics research and companion diagnostics enabling personalized therapies
3.3. Restraints
- 3.3.1. High R&D and regulatory compliance costs for theranostic agents and limited reimbursement clarity
- 3.3.2. Infrastructure gaps and limited access to advanced molecular imaging in emerging markets
3.4. Opportunities
- 3.4.1. Innovation in biomarker discovery, AI-enabled diagnostics and combination theranostic platforms
- 3.4.2. Expansion into emerging markets and collaborations between imaging firms and pharma for companion diagnostics

Chapter 4. Global Theranostics Industry Analysis

4.1. Porter's 5 Forces Model
- 4.1.1. Bargaining Power of Buyer
- 4.1.2. Bargaining Power of Supplier
- 4.1.3. Threat of New Entrants
- 4.1.4. Threat of Substitutes
- 4.1.5. Competitive Rivalry
4.2. Porter's 5 Force Forecast Model (2024-2035)
4.3. PESTEL Analysis
- 4.3.1. Political
- 4.3.2. Economical
- 4.3.3. Social
- 4.3.4. Technological
- 4.3.5. Environmental
- 4.3.6. Legal
4.4. Top Investment Opportunities
4.5. Top Winning Strategies (2025)
4.6. Market Share Analysis (2024-2025)
4.7. Global Pricing Analysis And Trends 2025
4.8. Analyst Recommendation & Conclusion

Chapter 5. Global Theranostics Market Size & Forecasts by Application 2025-2035

5.1. Market Overview
5.2. Global Theranostics Market Performance - Potential Analysis (2025)
5.3. Oncology
- 5.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.3.2. Market size analysis, by region, 2025-2035
5.4. Neurology
- 5.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.4.2. Market size analysis, by region, 2025-2035
5.5. Cardiology
- 5.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.5.2. Market size analysis, by region, 2025-2035
5.6. Infectious Diseases
- 5.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 5.6.2. Market size analysis, by region, 2025-2035

Chapter 6. Global Theranostics Market Size & Forecasts by Technology & Product Type 2025-2035

6.1. Market Overview
6.2. Global Theranostics Market Performance - Potential Analysis (2025)
6.3. Genomics
- 6.3.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.3.2. Market size analysis, by region, 2025-2035
6.4. Proteomics
- 6.4.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.4.2. Market size analysis, by region, 2025-2035
6.5. Metabolomics
- 6.5.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.5.2. Market size analysis, by region, 2025-2035
6.6. Biomarkers
- 6.6.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.6.2. Market size analysis, by region, 2025-2035
6.7. Product Type: Instruments
- 6.7.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.7.2. Market size analysis, by region, 2025-2035
6.8. Product Type: Reagents
- 6.8.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.8.2. Market size analysis, by region, 2025-2035
6.9. Product Type: Software
- 6.9.1. Top Countries Breakdown Estimates & Forecasts, 2024-2035
- 6.9.2. Market size analysis, by region, 2025-2035

Chapter 7. Global Theranostics Market Size & Forecasts by Region 2025-2035

7.1. Theranostics Market, Regional Market Snapshot
7.2. Top Leading & Emerging Countries
7.3. North America Theranostics Market
- 7.3.1. U.S. Theranostics Market
  - 7.3.1.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.3.1.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.3.2. Canada Theranostics Market
  - 7.3.2.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.3.2.2. Product Type & End User breakdown size & forecasts, 2025-2035
7.4. Europe Theranostics Market
- 7.4.1. UK Theranostics Market
  - 7.4.1.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.4.1.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.4.2. Germany Theranostics Market
  - 7.4.2.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.4.2.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.4.3. France Theranostics Market
  - 7.4.3.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.4.3.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.4.4. Spain Theranostics Market
  - 7.4.4.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.4.4.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.4.5. Italy Theranostics Market
  - 7.4.5.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.4.5.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.4.6. Rest of Europe Theranostics Market
  - 7.4.6.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.4.6.2. Product Type & End User breakdown size & forecasts, 2025-2035
7.5. Asia Pacific Theranostics Market
- 7.5.1. China Theranostics Market
  - 7.5.1.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.5.1.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.5.2. India Theranostics Market
  - 7.5.2.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.5.2.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.5.3. Japan Theranostics Market
  - 7.5.3.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.5.3.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.5.4. Australia Theranostics Market
  - 7.5.4.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.5.4.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.5.5. South Korea Theranostics Market
  - 7.5.5.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.5.5.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.5.6. Rest of APAC Theranostics Market
  - 7.5.6.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.5.6.2. Product Type & End User breakdown size & forecasts, 2025-2035
7.6. Latin America Theranostics Market
- 7.6.1. Brazil Theranostics Market
  - 7.6.1.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.6.1.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.6.2. Mexico Theranostics Market
  - 7.6.2.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.6.2.2. Product Type & End User breakdown size & forecasts, 2025-2035
7.7. Middle East and Africa Theranostics Market
- 7.7.1. UAE Theranostics Market
  - 7.7.1.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.7.1.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.7.2. Saudi Arabia (KSA) Theranostics Market
  - 7.7.2.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.7.2.2. Product Type & End User breakdown size & forecasts, 2025-2035
- 7.7.3. South Africa Theranostics Market
  - 7.7.3.1. Application & Technology breakdown size & forecasts, 2025-2035
  - 7.7.3.2. Product Type & End User breakdown size & forecasts, 2025-2035

Chapter 8. Competitive Intelligence

8.1. Top Market Strategies
8.2. Siemens Healthineers AG
- 8.2.1. Company Overview
- 8.2.2. Key Executives
- 8.2.3. Company Snapshot
- 8.2.4. Financial Performance (Subject to Data Availability)
- 8.2.5. Product/Services Port
- 8.2.6. Recent Development
- 8.2.7. Market Strategies
- 8.2.8. SWOT Analysis
8.3. GE HealthCare Technologies Inc.
8.4. F. Hoffmann-La Roche Ltd.
8.5. Thermo Fisher Scientific Inc.
8.6. Abbott Laboratories
8.7. Philips Healthcare
8.8. Agilent Technologies, Inc.
8.9. Illumina, Inc.
8.10. Danaher Corporation
8.11. Qiagen N.V.
8.12. Bayer AG
8.13. Bracco Imaging S.p.A.
8.14. Cardinal Health, Inc.
8.15. PerkinElmer, Inc.
8.16. Lantheus Holdings, Inc.